Donor leukapheresis for T-cell receptor gene therapy for treatment of metastatic melanoma (skin cancer)

Donor leukapheresis for T-cell receptor gene therapy for treatment of metastatic melanoma (skin cancer) - Donor leukapheresis for T-cell receptor gene therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34342

Enrollment

Registered

2010-07-20

Start date

2010-10-06

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melanoma Skin cancer

Interventions

The patient will need to undergo leucapheresis (by means of a groin catheter or peripheral infusion).

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient with a stage IV melanoma Minimum age 18 ECOG performance status max. 1 HLA-A@-positive patients negative for hepatitis A, B, C and HIV Thrombocytes at least 100*109/L Erythrocytes at least ... *109/L Hemoglobin at least 5 mmol/L Leukocytes at least ... *109/L ALAT/ASAT less than three times the upper limit of normal creatinin clearance 50ml/min or more total bilirubin at least 20 um/L life expectancy at least three months patients using anticoagulans cannot attend in this study

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Succeeding of the test runs.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)